ASCENDIS PHARMA A/S - AMERICAN DEPOSITARY SHARES

Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults

11 سبتمبر 2024 16:37:50 بحسب Nasdaq GlobeNewswire

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

03 سبتمبر 2024 16:06:29 بحسب Nasdaq GlobeNewswire

Ascendis Pharma Reports Second Quarter 2024 Financial Results

03 سبتمبر 2024 16:04:32 بحسب Nasdaq GlobeNewswire

Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024

28 أغسطس 2024 07:30:00 بحسب Nasdaq GlobeNewswire

FDA Approves YORVIPATH® (Palopegteriparatide) as the First and Only Treatment for Hypoparathyroidism in Adults

12 أغسطس 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024

24 يونيو 2024 15:45:36 بحسب Nasdaq GlobeNewswire

Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

04 يونيو 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

03 يونيو 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024

30 مايو 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism

14 مايو 2024 13:31:44 بحسب Nasdaq GlobeNewswire

Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial

13 مايو 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024

09 مايو 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Ascendis Pharma Reports First Quarter 2024 Financial Results

02 مايو 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024

25 أبريل 2024 15:46:31 بحسب Nasdaq GlobeNewswire

United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

24 أبريل 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024

04 مارس 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results

07 فبراير 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

07 فبراير 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024

31 يناير 2024 15:15:00 بحسب Nasdaq GlobeNewswire

Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism

31 يناير 2024 15:01:00 بحسب Nasdaq GlobeNewswire